Pierre Colas

Dr. Pierre Colas

Sorbonne Université, CNRS, Station Biologique, UMR 8227, Place Georges Teissier, Roscoff, France

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1996 in Nature
Verified
Journal Article
Closed access
PDF file
PCPierre Colas
Pierre Colas
BCBarak Cohen
Barak Cohen
TJTimm Jessen
Timm Jessen
IGIrina Grishina
Irina Grishina
JMJohn McCoy
John McCoy
RBRoger Brent
Roger Brent

13 January 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
ARAnne-Laure Rérole
Anne-Laure Rérole
JGJessica Gobbo
Jessica Gobbo
ATAurelie De Thonel
Aurelie De Thonel
ESElise Schmitt
Elise Schmitt
JBJean Paul Pais de Barros
Jean Paul Pais de Barros
GCGarrido Carmen
Garrido Carmen
The inhibition of heat shock protein 70 (HSP70) is an emerging strategy in cancer therapy. Unfortunately, no specific inhibitors are clinically available. By yeast two-hybrid screening, we have identified multiple peptide aptamers that bind HSP70. When expressed in human tumor cells, two among these peptide aptamers—A8 and A17—which bind to the peptide-binding and the ATP-binding domains of HSP70, respectively, specifically inhibited the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by anticancer drugs. The 13-amino acid peptide from the variable region of A17 (called P17) retained the ability to specifically inhibit HSP70 and induced the regression of subcutaneous tumors in vivo after local or systemic injection. This antitumor effect was associated with an important recruitment of macrophages and T lymphocytes into the tumor bed. Altogether, these data indicate that peptide aptamers or peptides that target HSP70 may be considered as novel lead compounds for cancer therapy. Cancer Res; 71(2); 484–95. ©2011 AACR.

1 April 2006 in Drug Discovery Today
Verified
Journal Article
Closed access
IBIvan C. Baines
Ivan C. Baines
PCPierre Colas
Pierre Colas

1 February 2012 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
AHAmel Hamdi
Amel Hamdi
PCPierre Colas
Pierre Colas

11 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
VGVincent J. Guen
Vincent J. Guen
CGCarly Gamble
Carly Gamble
MFMarc Flajolet
Marc Flajolet
SUSheila Unger
Sheila Unger
ATAurélie Thollet
Aurélie Thollet
PCPierre Colas
Pierre Colas
Significance: STAR syndrome is an X-linked dominant developmental disorder caused by mutations in FAM58A , which codes for an orphan cyclin with undescribed functions. Here we demonstrate that cyclin M interacts with CDK10 (one of the last orphan CDKs) to form a novel cyclin-dependent kinase. CDK10 is known to be involved in the control of cell division and in the resistance of certain breast cancers to endocrine therapy. We show that CDK10/cyclin M phosphorylates and positively regulates the degradation of ETS2, a transcription factor that plays key roles in cancer and development. These results shed light on the molecular mechanisms underlying STAR syndrome, and they pave the way for the exploration of the functions of the CDK10/cyclin M kinase.

24 November 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BCBarak A. Cohen
Barak A. Cohen
PCPierre Colas
Pierre Colas
RBRoger Brent
Roger Brent
Understanding the genetic networks that operate inside cells will require the dissection of interactions among network members. Here we describe a peptide aptamer isolated from a combinatorial library that distinguishes among such interactions. This aptamer binds to cyclin-dependent kinase 2 (Cdk2) and inhibits its kinase activity. In contrast to naturally occurring inhibitors, such as p21Cip1, which inhibit the activity of Cdk2 on all its substrates, inhibition by pep8 has distinct substrate specificity. We show that the aptamer binds to Cdk2 at or near its active site and that its mode of inhibition is competitive. Expression of pep8 in human cells retards their progression through the G1 phase of the cell cycle. Our results suggest that the aptamer inhibits cell-cycle progression by blocking the activity of Cdk2 on substrates needed for the G1-to-S transition. This work demonstrates the feasibility of selection of artificial proteins to perform functions not developed during evolution. The ability to select proteins that block interactions between a gene product and some partners but not others should make sophisticated genetic manipulations possible in human cells and other currently intractable systems.